Jiangsu Hengrui Pharmaceuticals' (SHA:600276, HKG:1276) subsidiary, Guangdong Hengrui Medicine, received approval from China's National Medical Products Administration for the clinical trial of the drug combination of SHR-1819 injection and SHR-1905 injection, according to a Shanghai bourse filing on Tuesday.
The drug combination will be tested as a treatment for atopic dermatitis.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.